Heritable Thrombophilia-Hypofibrinolysis and Osteonecrosis of the Femoral Head
- 1 May 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 466 (5) , 1034-1040
Abstract
Same measures in sex- and race-matched healthy control subjects. Heritable thrombophilic Factor VIII and hypofibrinolytic Lp(a) were more frequently high in the 71 patients with idiopathic osteonecrosis than in control subjects. High Factor VIII, Factor V Leiden heterozygosity, and resistance to activated protein C, all heritable thrombophilias, were more frequently present in the 62 patients with secondary osteonecrosis than in control subjects. Our data suggest inherited thrombophilia and hypofibrinolysis are risk factors for both idiopathic and secondary osteonecrosis of the head of the femur. Level of Evidence: Level IV, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence....Keywords
This publication has 85 references indexed in Scilit:
- Lp(a) Lipoprotein and Plasminogen Activity in Patients with Different Etiology of Ischemic StrokeCerebrovascular Diseases, 2006
- THE JOHN CHARNLEY AWARD: Heritable Thrombophilia and Development of Thromboembolic Disease after Total Hip ArthroplastyClinical Orthopaedics and Related Research, 2005
- ENHANCED TISSUE FACTOR PATHWAY INHIBITOR RESPONSE AS A DEFENSE MECHANISM AGAINST ONGOING LOCAL MICROVASCULAR EVENTS OF LEGG-CALVE-PERTHES DISEASEPediatric Hematology and Oncology, 2005
- Factor V Leiden and Prothrombin Gene MutationClinical Orthopaedics and Related Research, 2004
- Experimentally gained insight – based proposal apropos the treatment of osteonecrosis of the femoral headMedical Hypotheses, 2004
- Thrombotic and fibrinolytic alterations in the aseptic necrosis of femoral headBlood Coagulation & Fibrinolysis, 2003
- Hypofibrinolysis, Lipoprotein(a), and Plasminogen Activator InhibitorClinical Orthopaedics and Related Research, 2002
- Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophiliaExpert Opinion on Investigational Drugs, 2001
- Osteonecrosis: natural course and conservative treatmentDer Orthopäde, 2000
- Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolismThe Lancet, 1992